Pacific Edge has raised NZ$25.4 million through an oversubscribed placement priced at NZ$0.17 per share, aiming to bolster operations, support Medicare re-coverage efforts, and advance its bladder cancer diagnostic tests.
- NZ$25.4 million raised via oversubscribed placement
- Placement priced at 2.3% discount to prior close
- Retail offer planned to raise up to NZ$6 million
- Funds targeted at Medicare re-coverage and growth
- Strong institutional investor support underpins raise
Oversubscribed Placement Highlights Investor Confidence
Cancer diagnostics specialist Pacific Edge (NZX/ASX:PEB) has successfully increased its capital raise to NZ$25.4 million after strong demand pushed the placement beyond its initial target. The shares were priced at NZ$0.17 each, representing a modest 2.3% discount to the closing price before the raise was announced. The placement, completed on 12 May 2026, drew robust support from existing institutional and other investors, underscoring confidence in the company’s strategic direction.
The capital injection follows a recent announcement of a NZ$24 million raise, reflecting a growing appetite for Pacific Edge’s vision despite ongoing challenges around Medicare reimbursement. This raise builds on that momentum, with the company now also preparing a retail offer to eligible shareholders aiming to secure up to an additional NZ$6 million at the same price point. The retail offer details will be released imminently, providing existing investors an opportunity to participate further.
Capital to Fuel Medicare Re-Coverage and Market Expansion
Pacific Edge plans to deploy the fresh capital to sustain its operations and accelerate growth initiatives, particularly focusing on regaining Medicare coverage for its flagship bladder cancer diagnostic tests. Chairman Simon Flood emphasised the importance of this funding in consolidating the company’s market position, stating that the proceeds would support efforts to regain Medicare reimbursement and expand adoption among commercial payers in the US and Asia Pacific regions.
Chief Executive Dr Peter Meintjes highlighted the shifting clinical sentiment driven by emerging evidence from ongoing studies, which is gradually expanding the clinical utility of Pacific Edge’s Cxbladder tests. These non-invasive genomic urine tests are designed to improve risk stratification and patient outcomes for urothelial cancer, with over 130,000 tests ordered by more than 5,000 US urologists to date. The company’s presence extends across the US, Australasia, Israel, and parts of Asia and South America.
Building on Clinical Evidence and Market Reach
Supported by more than 20 years of research and over 25 peer-reviewed publications, Cxbladder’s inclusion in the American Urological Association’s Microhematuria Guideline marks a significant milestone. Pacific Edge continues to invest in evidence generation to drive broader uptake and improve patient health outcomes. The company’s laboratories in New Zealand and the US are CLIA certified, enabling it to deliver tests globally with high quality standards.
This capital raise follows the company’s earlier NZ$24 million equity raise announcement, which was aimed at shoring up finances amid a revenue drop linked to Medicare non-coverage. The ongoing efforts to secure Medicare re-coverage remain a critical focus, with a draft policy expected later in 2026 that could materially affect the company’s reimbursement landscape.
Bottom Line?
Pacific Edge’s oversubscribed placement provides a vital financial runway to pursue Medicare re-coverage and expand its bladder cancer diagnostics footprint, but regulatory outcomes and retail offer uptake remain key uncertainties.
Questions in the middle?
- Will the upcoming Medicare draft policy enable sustainable reimbursement for Cxbladder tests?
- How will the retail offer uptake influence Pacific Edge’s total capital raised and balance sheet?
- Can emerging clinical evidence translate into broader commercial payer adoption in key markets?